Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder

Figures & data

Figure 1. CONSORT diagram

Figure 2. Median active days by age, 12-week cohort vs. 24-week cohort

Figure 3. Median lessons completed by age, 12-week cohort vs. 24-week cohort

Figure 4. Patient engagement by lessons completed 12-week cohort vs. 24-week cohort

Figure 5. Engagement by week of treatment, 12-week cohort vs. 24-week cohort

Figure 6. Engagement by time of day, 12-week cohort vs. 24-week cohort

Figure 7. Correlation between module completion and abstinence among patients with 12 weeks vs. 24 weeks of treatment

Figure 8. Correlation between module completion and retention among patients with 12 weeks vs. 24 weeks of treatment

Table 1. Comparison of unique hospital encounters among patients with available insurance claims data

	Incidence
	1^st Cohort: 1 script N = 324 (12 weeks of treatment)	2^nd Cohort: 2 scripts N = 103 (24 weeks of treatment)
Unique hospital encounters (per patient)*	0.63 (95% CI: 0.49–0.80)	0.46 (95% CI: 0.29–0.73)
Percent reduction	Reference	27%

*Adjusted for age, sex, region, and pre-index unique hospital encounters.